Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2021 07:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma During American Association for Cancer Research (AACR) 2021 Annual Meeting

Median Duration of Response Not Reached at 28.1 Months of Median Study Follow Up in Cohort 2 of C-144-01 Study 36.4% Overall Response Rate; Continued Deepening of Responses SAN CARLOS, Calif.,...
March 15, 2021 16:01 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Appoints Igor Bilinsky as Chief Operating Officer

SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
March 10, 2021 17:28 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Present Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at American Association for Cancer Research (AACR) 2021 Annual Meeting

SAN CARLOS, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
March 01, 2021 16:01 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences

SAN CARLOS, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
February 25, 2021 16:01 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates

SAN CARLOS, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies...
February 18, 2021 07:30 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25, 2021

SAN CARLOS, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will...
January 19, 2021 08:56 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences

SAN CARLOS, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
December 28, 2020 07:30 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021

SAN CARLOS, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
December 14, 2020 07:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer

SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
November 30, 2020 07:21 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Present at Upcoming Conferences in December

SAN CARLOS, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...